Accurate diagnosis and prognosis of Alzheimer’s disease in primary care

MSCA (Marie Skłodowska-Curie)HORIZON-TMA-MSCA-PF-EFID: 101061836
EC Contribution
€2,069
Consortium Size
1 orgs
Start Year
2022
▶Summary

The overall objective of ADetect is to improve early diagnostics and prognostics of Alzheimer's disease in primary care by utilising novel plasma biomarkers and digital cognitive tests. Misdiagnosis of AD can reach >50% in primary care, which has important consequences both at the personal and societal level. Misdiagnosis, however, can be reduced by measuring AD-related pathology. The novel plasma biomarkers may be a cost-effective alternative given their low invasiveness and costs. However, they have not been validated in primary care yet, where much more diverse groups of people are managed. Further, the addition of brief cognitive digital tests that do not require involvement of a specialist may further improve the diagnostic accuracy. Based on the most cost-effective biomarkers, collected in unique prospective study performed in primary care, we will develop algorithms for diagnosis and prognosis of AD in a diverse population, and share them in the form of open and freely available apps. The algorithms will be validated against current standard of truth biomarkers and enhanced to give personalized risk assessments based on patients characteristics. Finally, we will investigate whether prospective use of these algorithms will improve treatment, management and care of patients. The development of easy-to-use tools, built on novel cognitive tests and plasma biomarkers, has huge potential to increase the diagnostic accuracy in primary care. A more accurate and timely diagnosis will lead to earlier initiation of currently available AD treatments. Further, when disease-modifying treatments become globally available, there will be an immense pressure on the healthcare system to identify eligible patients. Given the high prevalence of AD, its identification will primarily take place in primary care. With the easy-available proposed biomarkers, we have a great opportunity to develop the necessary tools for primary care to undertake this important task

Consortium (1)

🇸🇪 LUNDS UNIVERSITETSE
coordinator

Project Results (14)

Source: CORDIS, the EU research results database.

▶Publications (11)
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Nature Reviews Neurology· 2024DOI
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, Tharick A. Pascoal, Andréa Lessa Benedet, Nicholas J. Ashton, Thomas K. Karikari, Liana Apostolova, Melissa E. Murray, Inge Verberk, Jacob W. Vogel, Renaud La Joie, Serge Gauthier, Charlotte Teunissen, Gil D. Rabinovici, Henrik Zetterberg, Randall J. Bateman, Philip Scheltens, Kaj Blennow, Reisa Sperling, Oskar Hansson, Clifford R. Jack, Pedro Rosa-Neto
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
JAMA· 2024DOI
Sebastian Palmqvist, Pontus Tideman, Niklas Mattsson-Carlgren, Suzanne E. Schindler, Ruben Smith, Rik Ossenkoppele, Susanna Calling, Tim West, Mark Monane, Philip B. Verghese, Joel B. Braunstein, Kaj Blennow, Shorena Janelidze, Erik Stomrud, Gemma Salvadó, Oskar Hansson
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology
Molecular Neurodegeneration· 2024DOI
Joseph Therriault, Marcel S. Woo, Gemma Salvadó, Johan Gobom, Thomas K. Karikari, Shorena Janelidze, Stijn Servaes, Nesrine Rahmouni, Cécile Tissot, Nicholas J. Ashton, Andréa Lessa Benedet, Laia Montoliu-Gaya, Arthur C. Macedo, Firoza Z. Lussier, Jenna Stevenson, Paolo Vitali, Manuel A. Friese, Gassan Massarweh, Jean-Paul Soucy, Tharick A. Pascoal, Erik Stomrud, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Serge Gauthier, Henrik Zetterberg, Oskar Hansson, Kaj Blennow, Pedro Rosa-Neto
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Nature Aging· 2024DOI
Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, Jacob W. Vogel, Alexa Pichet Binette, Charles D. Chen, Andrew J. Aschenbrenner, Brian A. Gordon, Tammie L. S. Benzinger, David M. Holtzman, John C. Morris, Sebastian Palmqvist, Erik Stomrud, Shorena Janelidze, Rik Ossenkoppele, Suzanne E. Schindler, Randall J. Bateman, Oskar Hansson
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
Nature Medicine· 2024DOI
Nicolas R. Barthélemy, Gemma Salvadó, Suzanne E. Schindler, Yingxin He, Shorena Janelidze, Lyduine E. Collij, Benjamin Saef, Rachel L. Henson, Charles D. Chen, Brian A. Gordon, Yan Li, Renaud La Joie, Tammie L. S. Benzinger, John C. Morris, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Rik Ossenkoppele, Gil D. Rabinovici, Erik Stomrud, Randall J. Bateman, Oskar Hansson
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Molecular Neurodegeneration· 2024DOI
Juan Lantero-Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu-Gaya, Wagner S. Brum, Andrea L. Benedet, Niklas Mattsson-Carlgren, Pontus Tideman, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Nature Medicine· 2023DOI
Kanta Horie, Gemma Salvadó, Nicolas R. Barthélemy, Shorena Janelidze, Yan Li, Yingxin He, Benjamin Saef, Charles D. Chen, Hong Jiang, Olof Strandberg, Alexa Pichet Binette, Sebastian Palmqvist, Chihiro Sato, Pallavi Sachdev, Akihiko Koyama, Brian A. Gordon, Tammie L. S. Benzinger, David M. Holtzman, John C. Morris, Niklas Mattsson-Carlgren, Erik Stomrud, Rik Ossenkoppele, Suzanne E. Schindler, Oskar Hansson, Randall J. Bateman
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
Nature Aging· 2023DOI
Nicolas R. Barthélemy, Benjamin Saef, Yan Li, Brian A. Gordon, Yingxin He, Kanta Horie, Erik Stomrud, Gemma Salvadó, Shorena Janelidze, Chihiro Sato, Vitaliy Ovod, Rachel L. Henson, Anne M. Fagan, Tammie L. S. Benzinger, Chengjie Xiong, John C. Morris, Oskar Hansson, Randall J. Bateman, Suzanne E. Schindler
Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi‐cohort study
Alzheimer's & Dementia· 2023DOI
Gemma Salvadó, Victoria Larsson, Karly A Cody, Nicholas C Cullen, Erin M Jonaitis, Erik Stomrud, Gwendlyn Kollmorgen, Norbert Wild, Sebastian Palmqvist, Shorena Janelidze, Niklas Mattsson‐Carlgren, Henrik Zetterberg, Kaj Blennow, Sterling C Johnson, Rik Ossenkoppele, Oskar Hansson
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers
JAMA Neurology· 2023DOI
Niklas Mattsson-Carlgren, Gemma Salvadó, Nicholas J. Ashton, Pontus Tideman, Erik Stomrud, Henrik Zetterberg, Rik Ossenkoppele, Tobey J. Betthauser, Karly Alex Cody, Erin M. Jonaitis, Rebecca Langhough, Sebastian Palmqvist, Kaj Blennow, Shorena Janelidze, Sterling C. Johnson, Oskar Hansson
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
EMBO Molecular Medicine· 2023DOI
Gemma Salvadó, Rik Ossenkoppele, Nicholas J Ashton, Thomas G Beach, Geidy E Serrano, Eric M Reiman, Henrik Zetterberg, Niklas Mattsson‐Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson
▶Deliverables (2)
Communication, Dissemination & Exploitation Plan
Documents, reports
Data Management Plan
Documents, reports
▶Other Results (1)
Periodic Reporting for period 1 - ADetect (Accurate diagnosis and prognosis of Alzheimer’s disease in primary care)